Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

ElliottwaveForecast Apr. 1 at 4:14 PM

$JNJ favors rally targeting 256.3 or higher It was expected pullback in 3 swing into 229.32 or lower, which missed & turned higher. It ended correction at 232.01 low & favors rally targeting 256.3 - 263.71 area to extend January-2025 rally. #elliottwave #JNJ

0 · Reply

DragonAlgo Apr. 1 at 2:31 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-17 | Strike: $240.00 | Type: CALL Option Plan (premium): Entry: $9.70 Stop: $6.98 TP1: $12.61 TP2: $16.49 TP3: $23.28 Rules-based execution profile. 🔗 https://dragonalgo.com

0 · Reply

Skimman Apr. 1 at 11:11 AM

$JNJ $KVUE $SPX $SPY another Bitter Bear

0 · Reply

Suite510 Apr. 1 at 11:10 AM

$JNJ $KVUE $SPX $SPY Hey this sounds like Junk n Junk future with talc 🤣🚀 When a Georgia jury ordered Bayer to pay $2.1 billion to a single plaintiff in March 2025, the verdict sent shockwaves

0 · Reply

Dr_Stoxx Mar. 31 at 9:38 PM

$JNJ: @InvestorsBusinessDaily Stock of the Day -- looks like easy green into earnings. hashtag#IBDPartner @MarketSurge @InvestorsBusinessDaily

1 · Reply

ClinicalTrialsDaily Mar. 31 at 4:57 PM

$TAK Outstanding Phase 3 LATITUDE clinical efficacy for Zasocitinib. Generating up to 33.4% PASI 100 functionally obsoletes $AMGN Otezla. The incoming NCT06973291 head-to-head data against $BMY Sotyktu is the ultimate binary catalyst. Watch for \ $JNJ Icotyde as the primary out-of-class threat. Read more: www.clinicaltrialsdaily.com/zasocitinib-tyk2-plaque-psoriasis/

0 · Reply

hyenacorp Mar. 31 at 3:49 PM

$JNJ

0 · Reply

MorganHoratio Mar. 31 at 1:10 PM

$SYRE Big biotech read-through most are sleeping on: BTIG just reiterated Buy / $70 PT after $RPRX + $JNJ teamed up on JNJ-4804 (dual IL-23 + TNF approach). That’s not just noise — it validates the combo therapy thesis in IBD, exactly where $SYRE is positioning. Why it matters: Big Pharma doubling down on multi-pathway biology Direct sympathy to $SYRE’s SPY120/130/230 combo platform DUET data from $JNJ later this year = potential sentiment catalyst Pipeline timeline: 2Q26: SPY001 (anti-CD47) PoC readout 2026: SPY002 (TL1A) + SPY003 (IL-23) data follow 2027: Full Phase 2 combo data (SKYLINE) Underrated angle: TL1A is part of the TNF superfamily — historically validated pathways = higher probability setups. If TNF worked, TL1A could be next. More shots on goal: 3Q26: SPY072 (RA) 4Q26: axSpA + PsA data Translation: This isn’t a single binary biotech — it’s a platform bet with multiple catalysts lined up. Market hasn’t fully priced this in yet. Stay alert.

0 · Reply

Quantumup Mar. 31 at 11:41 AM

BTIG reiterated $SYRE Buy-$70 after $RPRX announced a co-funding agreement w/ $JNJ for the devt of JNJ-4804 (co-antibody of remfya+golimumab [IL-23+TNF]). Here's what BTIG had to say in its note: https://x.com/Quantumup1/status/2038944109151261006?s=20

0 · Reply

DragonAlgo Mar. 31 at 5:52 AM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-02 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $2.64 Stop: $1.90 TP1: $3.43 TP2: $4.49 TP3: $6.34 🔗 https://dragonalgo.com

0 · Reply

My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 12 Buys

ARCC AVGO BP BX CSWC HTGC MAIN

Mar 31, 2026, 2:03 AM EDT - 1 day ago

Johnson & Johnson: The Return Of The Dividend King

Mar 30, 2026, 9:14 AM EDT - 2 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 30, 2026, 7:15 AM EDT - 2 days ago

Dividend Investing Is Winning In 2026 - Move Over, Tech And AI

AMZN CRM ED GOOGL MCD META MSFT

Mar 28, 2026, 10:45 PM EDT - 3 days ago

Procter & Gamble, Johnson & Johnson Among 9 Companies To Announce Dividend Increases In The First Half Of April

Mar 28, 2026, 10:00 AM EDT - 4 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 4 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 5 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 25, 2026, 9:43 PM EDT - 6 days ago

Johnson & Johnson: Deserves A Place In Conservative Dividend Growth Portfolios

Mar 24, 2026, 8:45 AM EDT - 8 days ago

Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi

PTGX

Mar 21, 2026, 2:12 AM EDT - 11 days ago

Best Dividend Aristocrats As Of March 20, 2026

ABT ADM ADP ALB AMCR AOS APD

Mar 19, 2026, 1:00 PM EDT - 13 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 13 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 14 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 14 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 14 days ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 14 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 16 days ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 19 days ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 20 days ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

Mar 11, 2026, 9:36 AM EDT - 21 days ago

Goldman Sachs Large Cap Equity Fund Q4 2025 Portfolio Activity

AMD APD CAT DHI FISV LLY

Mar 10, 2026, 5:10 PM EDT - 21 days ago

Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 26 days ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 26 days ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 27 days ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 2:02 PM EST - 4 weeks ago

Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 1:18 PM EST - 4 weeks ago

Wasatch Global Value Fund Q4 2025 Performance Review

BABA C T VICI

Mar 3, 2026, 8:03 AM EST - 4 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 4 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 27, 2026, 12:21 PM EST - 4 weeks ago

Best Dividend Aristocrats For March 2026

ABBV ABT ADM ADP AFL ALB AMCR

Feb 26, 2026, 5:34 PM EST - 4 weeks ago

2 Dividend Kings That Could Easily Keep The Growth Streak Alive

AWR DOV GPC PG

Feb 26, 2026, 2:30 PM EST - 4 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 5 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 5 weeks ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 5 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 5 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 5 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:30 PM EST - 5 weeks ago

Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)

Feb 19, 2026, 5:00 PM EST - 5 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 5 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 5 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 19, 2026, 9:15 AM EST - 5 weeks ago

2 High-Yield CEFs To Enhance Your Retirement Income

AMLP ASGI BIZD BTI MO SCHD T

Feb 18, 2026, 10:44 AM EST - 6 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 6 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 6 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 6 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 6 weeks ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 17, 2026, 6:23 AM EST - 6 weeks ago

Dividend Income: Lanny's December 2025 Summary

ADM AFL EMR GWW IBM LYB MCD

Feb 13, 2026, 4:19 PM EST - 6 weeks ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 6 weeks ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

ElliottwaveForecast Apr. 1 at 4:14 PM

0 · Reply

DragonAlgo Apr. 1 at 2:31 PM

0 · Reply

Skimman Apr. 1 at 11:11 AM

$JNJ $KVUE $SPX $SPY another Bitter Bear

0 · Reply

Suite510 Apr. 1 at 11:10 AM

$JNJ $KVUE $SPX $SPY Hey this sounds like Junk n Junk future with talc 🤣🚀 When a Georgia jury ordered Bayer to pay $2.1 billion to a single plaintiff in March 2025, the verdict sent shockwaves

0 · Reply

Dr_Stoxx Mar. 31 at 9:38 PM

$JNJ: @InvestorsBusinessDaily Stock of the Day -- looks like easy green into earnings. hashtag#IBDPartner @MarketSurge @InvestorsBusinessDaily

1 · Reply

ClinicalTrialsDaily Mar. 31 at 4:57 PM

0 · Reply

hyenacorp Mar. 31 at 3:49 PM

$JNJ

0 · Reply

MorganHoratio Mar. 31 at 1:10 PM

0 · Reply

Quantumup Mar. 31 at 11:41 AM

0 · Reply

DragonAlgo Mar. 31 at 5:52 AM

0 · Reply

The__short_squeezer Mar. 30 at 8:44 PM

$NFLX $GOOG $TSLA $LLY $JNJ

0 · Reply

Lowkeyoptions Mar. 30 at 8:42 PM

$BFRG Based on 2024–2025 revenue data, the top pharmaceutical companies are dominated by Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Roche. These companies lead in manufacturing vaccines, oncology drugs, and innovative therapies, with several, particularly Pfizer, rebounding from lower COVID-19 product demand. Top 5 Pharmaceutical Companies (by 2024/2025 Revenue): $PFE Often leads by revenue due to COVID-19 vaccines and vaccines like Prevnar, though facing pressure to diversify. $MERCK (USA): Known for cancer immunotherapy Keytruda, which has driven significant growth, placing them high in the rankings. $JNJ Johnson & Johnson (USA): A diversified healthcare leader with strong positions in pharmaceuticals and medical $ABBV (USA): Known for immunology treatments like Humira, maintaining a top spot despite patent challenges. $RHHBY Roche (Switzerland): A leader in oncology and diagnostics, often ranking top five due to its specialized, high-cost therapies.

0 · Reply

yellowstar16 Mar. 30 at 7:57 PM

$JNJ been holding up well in this market.

0 · Reply

booboobeargimmy Mar. 30 at 7:48 PM

$JNJ taking a position here

0 · Reply

JJBurch Mar. 30 at 3:15 PM

$OSRH 🚨 🚨 🚨 ‼️ ‼️ 🚀 buy $OSRH ready for commercialization now!! My friends. Last call to go ALL IN $OSRH!!! $JNJ $MRK $TSLA $GCTK

0 · Reply

jmf123 Mar. 30 at 2:21 PM

$AMGN $ICU $JNJ $MRNA $TAK I so agree. A $30 stock price would only be a $100 million market cap.

1 · Reply

SparkyReturns Mar. 30 at 2:03 PM

$ICU This is no joke. Sleeper of the century. 10M Market Cap for a company that will earn billions in revenue in a few years. Up 12% so far today on great news. $MRNA $AMGN $JNJ $TAK

0 · Reply

ArthurOwens63 Mar. 30 at 1:59 PM

$JNJ defensive heavyweight acting like capital wants stability watch for steady trend confirmation over excitement

0 · Reply

DragonAlgo Mar. 30 at 1:32 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-02 | Strike: $242.50 | Type: CALL Option Plan (premium): Entry: $2.42 Stop: $1.74 TP1: $3.15 TP2: $4.11 TP3: $5.81 System-defined risk profile. 🔗 https://dragonalgo.com

0 · Reply

LandonCapital Mar. 30 at 11:53 AM

$JNJ https://landoncapital.net/putting-your-money-where-your-mouth-is-royalty-pharma-partners-with-jj-on-500m-drug-development-deal/

0 · Reply

TheRealShortSqueezy Mar. 30 at 11:21 AM

$ELAB Bullish setup building here 👀 PMGC Holdings is a microcap biotech focused on muscle preservation and metabolic health, with assets targeting pathways like myostatin, especially relevant alongside the rise of GLP-1 weight loss drugs. 📰 Last Friday, their subsidiary NorthStrive updated a licensing agreement with MOA Life to advance EL-22 / EL-32, aimed at preventing muscle loss during GLP-1 treatments. 📰 Today. they reported 2025 annual results showing assets up ~43% YoY to ~$13.8M, signaling continued expansion of their asset base. Currently sitting around 3$, it could be interesting to see if they fill the gap to 6$. Peers: $LLY $JNJ $PFE $MRK

0 · Reply

Nasfact Mar. 30 at 10:35 AM

$SLS $JNJ $PFE

0 · Reply

Market Cap	584.06B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.26
Forward PE	20.83
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	3,065,325
Avg Vol	8,906,432
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	93%
Beta	0.34
Analysts	Strong Sell
Price Target	$243.16